HEALTHCARE
May 21, 2019
(AETOS Wire) -- Masimo (NASDAQ: MASI) announced today the results of a study published in BMC Anesthesiology in which clinicians at Peking Union Medical College in Beijing evaluated the ability of noninvasive and continuous hemoglobin monitoring with Masimo SpHb® to help clincians estimate when to conduct invasive hemoglobin measurement to detect possible anemia in patients undergoing spine or cytoreductive surgery.1 Noting that because of the “invasive, time-consuming and intermittent” nature of invasive blood sampling, clincians often forgo these “objective indications” when making transfusion decisions during surgery,......
May 20, 2019
Air Pollution: NLNG Earns N36tn from Flare Gas Monetisation
Ahead of the 2019 World Environment Day (WED) celebration, which amplifies the clamour for players in the petroleum industry to curb the rising level of global air pollution, Nigeria Liquefied Natural Gas (NLNG) Limited has declared over $100 billion or N36 trillion gross income from gas"...
Read More >>May 20, 2019
- Results of pivotal Phase III SENSCIS® trial published today in the New England Journal of Medicine (NEJM) and presented at the American Thoracic Society Conference in Dallas, USA
- Interstitial lung disease (ILD) is a key driver of mortality in people living with systemic sclerosis (SSc) – also known as scleroderma – and the... Read More >>
May 20, 2019
Age, Gender, Disease Severity Impact Adherence to Long-Term PAP Therapy More Than Previously Thought
(AETOS Wire) -- ResMed (NYSE: RMD, ASX: RMD) today revealed several demographic and clinical factors affect adherence to PAP (positive airway pressure) therapy, according to a study it presented at the American Thoracic Society's ATS 2019 International"...
Read More >>May 20, 2019
(AETOS Wire) -- Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE:TAK) today announced that the company will present data at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO), May 31-June 4 in Chicago and the 24th Congress of the European Hematology Association (EHA), June 13-16 in Amsterdam. “We look forward to presenting data at ASCO and EHA that illustrate the continued progress of our portfolio in both clinical research and real-world settings in solid tumors and blood cancers,” said Phil Rowlands, Ph.D., Head, Oncology Therapeutic Area Unit, Takeda. “These data demonstrate our continued commitment......
May 20, 2019
(AETOS Wire)-- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced further results from the Phase 3b head-to-head VARSITY study, which demonstrated that the gut-selective biologic vedolizumab (Entyvio®) was superior to the anti-tumor necrosis factor-alpha (anti-TNFα) biologic adalimumab (Humira®) in achieving clinical remission* at week 52 in patients with moderately to severely active ulcerative colitis (UC).1 New exploratory data showed that a greater proportion of patients receiving vedolizumab intravenous (IV) achieved clinical response** at week 14 compared to those treated with......
May 18, 2019
HMO Total Health Trust Holds Business Forum
Leading Health Maintenance Organisation, Total Health Trust Limited recently held its annual business forum with this year’s edition focusing on value creation and wealth preservation by Nigeria corporates faced with a challenging macroeconomic landscape.
Among"...
Read More >>May 18, 2019
WHO to dispatch medical aid to Libya in the coming week
The World Health Organization (WHO) office in Libya said Wednesday that a shipment consisting of medicines sufficient to treat thousands of patients will reach 40 primary health care centres and hospitals in Libya by this week.
WHO"...
Read More >>May 18, 2019
(AETOS Wire)-- Takeda Pharmaceutical Company Limited (TOKYO:4502/NYSE:TAK) (“Takeda”) and the London School of Hygiene & Tropical Medicine (LSHTM) will announce today at the evening reception, hosted by the Embassy of Japan in the United Kingdom, the establishment of the Takeda Chair in Global Child Health, endowed by a £3 million donation by Takeda to LSHTM. The School’s first fully endowed corporate chair, it will support vital research into reducing 5.3 million child deaths in low and middle-income countries. Takeda’s donation will enable LSHTM to recruit a world-class researcher and educator to join its......
May 18, 2019
(AETOS Wire) -- Eyenuk Inc., a global artificial intelligence (AI) medical technology and services company and the leader in real-world applications for AI Eye Screening™, announced today results of its expansion into Germany. Since adopting the EyeArt AI Eye Screening System in October 2018, Diabetes Center Mergentheim has screened thousands of diabetic patients, identifying approximately 10% with cases of referable diabetic retinopathy (DR). The center is the first dedicated diabetic clinic in Germany to use artificial intelligence for screening of diabetic retinopathy, the leading cause of vision loss in working-age adults.1 The EyeArt......
